A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
Figure 3-2, Outcome Measures Framework - Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User's Guide, 3rd Edition, Addendum 2 - NCBI Bookshelf
Secondary outcome measure. The median follow-up of 15.7 months. The... | Download Scientific Diagram
Articles Archives - Page 2 of 10 - GNS
Summary of the clinical trials and outcome measures for combination... | Download Table
Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer - Clinical Lung Cancer
PLOS ONE: Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
JCI Insight - A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Checkmate 9LA 1L NSCLC Efficacy Data | OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
JCI Insight - A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Bavencio HCP UC Efficacy
Event-free and overall survival of all eligible patients on the study. | Download Scientific Diagram
Evaluating eligibility criteria of oncology trials using real-world data and AI | Nature
Drug Trials Snapshot: LONSURF | FDA
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis | Prostate Cancer and Prostatic Diseases
Publications | Flatiron Health
Bavencio HCP UC Efficacy
Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer - Clinical Lung Cancer
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Overall Survival Results with KISQALI® (ribociclib)
LENVIMA® (lenvatinib) HCP Website | Clinical Study Design
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial - The Lancet Oncology
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
